Ramamoorthy Nagasubramanian, MD
Recent results published in The Lancet Oncology
showed that larotrectinib induced an objective response rate (ORR) of 93% in pediatric patients with TRK
fusion-positive solid tumors. These results have set a new precedent for the simultaneous development of agents in pediatric and adult patients, said Ramamoorthy Nagasubramanian, MD, one of the investigators on the study.
, Nagasubramanian, chief, Division of Hematology/Oncology, Department of Pediatrics, Nemours Children’s Health System, discussed the results of this phase I/II study of larotrectinib in pediatric patients.
OncLive: Can you provide some background information on the trial?
: Initially, when this trial opened, it was open to children with solid tumors who were advanced and either refractory, or not responding to primary frontline treatments. Since we knew that this drug was an agent targeted toward TRK
fusions, we knew that we would find some pediatric tumors that carry these fusions and may respond well. We did not know the actual incidence of TRK
fusions in pediatric cancers, so the study initially started enrolling all patients with solid tumors. We knew that there were some rare pediatric tumors that harbored TRK
fusions, so we hoped to see those patients included on the trial, which was the case.
... to read the full story